These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 30743093)

  • 21. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
    Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
    Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
    Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.
    Butler K; Larney S; Day CA; Burns L
    Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reviewing harm reduction for people who inject drugs in Asia: the necessity for growth.
    Stone KA
    Harm Reduct J; 2015 Oct; 12():32. PubMed ID: 26472335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
    Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
    Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
    Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
    Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
    Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
    Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
    Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
    PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.
    van Santen DK; Lodi S; Dietze P; van den Boom W; Hayashi K; Dong H; Cui Z; Maher L; Hickman M; Boyd A; Prins M
    Addiction; 2023 Jun; 118(6):1116-1126. PubMed ID: 36710474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.
    Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C
    Int J Drug Policy; 2019 Oct; 72():106-113. PubMed ID: 31178254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.
    MacArthur GJ; van Velzen E; Palmateer N; Kimber J; Pharris A; Hope V; Taylor A; Roy K; Aspinall E; Goldberg D; Rhodes T; Hedrich D; Salminen M; Hickman M; Hutchinson SJ
    Int J Drug Policy; 2014 Jan; 25(1):34-52. PubMed ID: 23973009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.
    Stone J; Fraser H; Young AM; Havens JR; Vickerman P
    Int J Drug Policy; 2021 Feb; 88():102707. PubMed ID: 32151496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Service utilization and cost of implementing a comprehensive HIV prevention and care program among people who inject drugs in Delhi, India.
    Sebastian MP; Dasgupta A; Saraswati LR; Singh A; Sharma V; Madan I; Tun W; Pulerwitz J; Thior I; Sarna A
    Harm Reduct J; 2017 Jun; 14(1):38. PubMed ID: 28615077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada.
    Jacka B; Larney S; Degenhardt L; Janjua N; Høj S; Krajden M; Grebely J; Bruneau J
    Am J Public Health; 2020 Jan; 110(1):45-50. PubMed ID: 31725310
    [No Abstract]   [Full Text] [Related]  

  • 37. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
    Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
    Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The furthest left behind: the urgent need to scale up harm reduction in prisons.
    Sander G; Murphy F
    Int J Prison Health; 2017 Sep; 13(3-4):185-191. PubMed ID: 28914120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.
    Grillon C; Krishtel PR; Mellouk O; Basenko A; Freeman J; Mendão L; Andrieux-Meyer I; Morin S
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25060. PubMed ID: 29633580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.